Report Details
What does the future hold for biobanks? Visiongain's report shows you potential revenues and trends to 2022. Find data, forecasts and discussions for biobanking in medicine.
Discover sales predictions at overall market, submarket and national levels to 2022. Our study gives you business research, analysis and opinion for applications in medical research, pharmaceuticals and diagnostics.
How will the biobanking industry perform? Receive forecasts for human tissue banking, stem cell banking, private cord banking, other services (e.g., DNA and RNA storage), commercial biobanks, academic collections and other operations. You find revenues and discussions.
R&D applications are multiplying and widening. Assess contributions of biobanks in understanding disease, drug discovery, drug development and biomarkers. This decade will result in technological and organisational progress, public and private, benefiting healthcare.
Our report discusses Cryo-Cell International, Cord Blood America, Tissue Solutions, Asterand, ViaCord, LifebankUSA, China Cord Blood and other organisations. See activities and outlooks.
Biobanks and biorepositories will become more important to medical R&D and human healthcare. Biological science and technology stand to benefit. Discover the prospects.
Visiongain's study provides data, analysis and opinion aiming to help your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), news and views. You receive 72 tables and charts and six research interviews.
Advantages of Biobanking for Medicine: Technology and Market 2012-2022 for your work
In particular, this study gives you the following knowledge and benefits:
• Find revenue predictions to 2022 for the overall world market and submarkets, seeing growth trends
• Assess companies in medical biobanking, discovering activities and outlooks
• See revenue forecasts to 2022 in leading countries for human tissue banking - US, Japan, Germany,France, UK, Spain, Italy, China and India
• Review developmental trends for biobanks - technologies and services
• Investigate competition and opportunities influencing commercial results
• Find out what will stimulate and restrain that industry and market
• View expert opinions from our survey of that biotechnology sector.
There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse developments and prospects, helping you to stay ahead.
Gain business research, data and analysis for medical biobanking
Our study is for everybody needing industry and market analyses for medical biobanks. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Blood Supply, Tissue Banking And Transplantation Industry
Table of Contents
1. Executive Summary
1.1 Summary Points of this Report
1.2 Aims, Scope and Format of the Report
1.2.1 Speculative Aspects of Assessing the Biobanking Market
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
1.3.1 Human Tissue Banking Market
1.3.2 Stem Cell Banking Market
2. Introduction to Biobanking
2.1 Biobanking
2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-Fold Character
2.3 Key Features
2.4 Classification of Biobanks
2.4.1 Volunteer Groups
2.4.1.1 Population-Based Biobanks
2.4.1.2 Disease-Oriented Biobanks
2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-Based Research
3. Biobanking and the Pharmaceutical Industry
3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways
3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery
3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies
4. Biobanking Associated Market: Systems, Software, Consumables and Services Associated with Biobanking
4.1 Overview
4.2 Systems/Technologies
4.2.1 Automated Liquid Handling
4.2.1.1 Frozen Aliquotting: New Technology in Development
4.2.2 Storage
4.2.2.1 Ultra-Low Temperature Freezing
4.2.2.2 Room-Temperature Storage
4.2.3 RFID and Tagging Technologies
4.3 Software
4.3.1 Laboratory Information Management System (LIMS)
4.3.1.1 LIMS Functions
4.4 Consumables
4.5 Services
5. The World Medical Biobanking Market to 2022
5.1 Current State of the Biobanking Market
5.2 Geographical Footprint
5.3 Growing Demand for Biobank Resources
5.4 Revenue Forecast for Overall Market
5.4.1 Scope and Limitations
5.4.2 Biobanking Market, 2011-2022
5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016
5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022
5.5 Commercial Biobanks: New Resources for Research
6. Human Tissue Banking Market
6.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2022
6.1.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2016
6.1.2 Revenue Forecast for Overall Human Tissue Banking Market, 2017-2022
6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2011-2022
6.2.1 Revenue Forecast for Commercial Human Tissue Banking Market, 2011-2016
6.2.2 Revenue Forecast for Commercial Human Tissue Banking Market, 2017-2022
6.2.3 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2011-2016
6.2.4 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2017-2022
6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2011-2022
6.4 Some Commercial Participants in the Human Tissue Banking Market
6.4.1 Business Models of Companies in the Biobanking Market
6.4.2 Tissue Solutions
6.4.2.1 Overview
6.4.2.2 Global Presence
6.4.2.3 Products and Services
6.4.2.3.1 Banked Samples
6.4.2.3.2 Prospective Samples
6.4.2.3.3 Fresh Samples
6.4.2.3.4 Freshly Isolated and Primary Cells
6.4.2.3.5 Services
6.4.2.4 Strengths and Capabilities
6.4.2.5 Future Outlook
6.4.3 Asterand
6.4.3.1 Overview
6.4.3.2 Global Presence
6.4.3.3 Products and Services
6.4.3.3.1 XpressBANK
6.4.3.3.2 ProCURE
6.4.3.3.3 PhaseZERO
6.4.3.3.4 BioMAP
6.4.3.4 Asterand: Raised Barriers for New Market Entrants?
6.4.3.5 Financial Performance
6.4.3.6 Future Outlook
7. Stem Cell Banking
7.1 Overview
7.2 Revenue Forecast for Overall Stem Cell Banking Market, 2011-2022
7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016
7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022
7.3 Stem Cell Banks for Research: High Growth Possible
7.4 Umbilical Cord Blood Banking for Stem Cells
7.4.1 Blood Banks: Private vs. Public
7.4.2 Biological Insurance: Private Blood Banking
7.4.3 Umbilical Cord Banking: The Controversies
7.4.3.1 US Oversight of Cord Blood Stem Cells
7.4.4 Revenue Forecast for Private Cord Blood Banking Market, 2011-2016
7.4.5 Revenue Forecast for Private Cord Blood Banking Market, 2017-2022
7.4.6 Companies in the Field
7.4.6.1 Cord Blood America: Looking Towards the Chinese Market
7.4.6.2 ViaCord: 145,000 Blood Units in Storage
7.4.6.3 Cryo-Cell International: The First Cord Blood Bank
7.4.6.4 Stem Cell Authority: Exclusive Stem Cells
7.4.6.5 LifebankUSA: Placenta-Cord Banking
7.4.6.6 Biogenea-Cellgenea
7.4.6.7 China Cord Blood Corp
7.4.6.8 Cryo-Save
7.4.6.9 Thermogenesis
7.5 Gene/DNA Banking
8. Industry Trends
8.1 Automated Biobanking
8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking
8.1.2 Addressing Sample Storage and Tracking Issues
8.2 Green Banking
8.3 Creation of National Biobanks
8.4 HIPAA Amendments
9. Qualitative Analysis of the Biobanking Sector
9.1 Strengths
9.1.1 Wealth of Information for Genetic Research
9.1.2 Potential to Change Treatments
9.1.3 Many Governments Support Biobanking
9.2 Weaknesses
9.2.1 Quality Concerns for Some Existing Biospecimen Collections
9.2.2 Lack of Standardisation and Harmonisation of Best Practices
9.2.3 Limited Sharing and Linkage of Biobanks
9.3 Opportunities
9.3.1 Genome-Wide Association Studies (GWAS)
9.3.2 Personalised Medicine
9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach
9.4 Threats
9.4.1 Ethical and Regulatory Issues
9.4.1.1 Limitations of Informed Consent in Biobanking
9.4.1.2 Confidentiality and Security to Prevent Improper Use
9.4.2 Social and Cultural Issues
9.4.3 Ownership Issues
9.4.4 Funding
10. Research Interviews from Our Survey
10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry
10.1.2 On Commercial Aspects of Biobanking
10.1.3 On the Business of Tissue Solutions
10.1.4 On the Attractiveness of Human Tissue Banking
10.1.5 On the Future of the Biobanking Market
10.2 Dr Angel García Martín, Director, Inbiomed
10.2.1 On the Importance of Biobanking in the Pharmaceutical Industry
10.2.2 On the Use of Technology in Biobanking
10.2.3 On Increased Recognition of Biobanking and Harmonisation of Samples
10.2.4 On the Use of Biobanks by the Pharmaceutical Industry
10.2.5 On Private Biobanks and Scale of Operations
10.2.6 On Commercial and Public Biobanking and Legislation
10.2.7 On the Most Attractive Segment in Commercial Biobanking
10.2.8 On the Future of Biobanking: Drivers and Challenges
10.3 Dr Piet Smet, Director, Business Development, BioStorage Technologies
10.3.1 On Defining Biorepositories and Biobanks
10.3.2 On the Services of Biostorage
10.3.3 On Main Customers for Biostorage
10.3.4 On the Importance of Biorepositories in Research and Industry
10.3.5 On Technology Use in Biobanks
10.3.6 On Increased Recognition of Biobanking and Harmonisation of Samples
10.3.7 On the Use of Biobanks by the Pharmaceutical Industry
10.3.8 On Private Biobanks and Scale of Operations
10.3.9 On Commercial and Public Biobanking and Legislation
10.3.10 On the Most Attractive Segment in Commercial Biobanking
10.3.11 On Biobanking in 2020
10.3.12 On Drivers and Challenges in the Sector
10.4 Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems
10.4.1 On the Services of SampleNavigator
10.4.2 On Main Customers for SampleNavigator
10.4.3 On the Importance of Biorepositories in Research and Industry
10.4.4 On Technology Use in Biobanks
10.4.5 On Increased Recognition of Biobanking and Harmonisation of Samples
10.4.6 On the Use of Biobanks by the Pharmaceutical Industry
10.4.7 On Commercial Biorepositories/Banks and Scale of Operations
10.4.8 On Commercial and Public Biobanking
10.4.9 On the Most Attractive Segment in Commercial Biobanking
10.4.10 On Biobanking in 2020
10.4.11 On Drivers and Challenges in the Sector
10.5 Mr Rob Fannon, Clinical Operations Manager, BioServe
10.5.1 On the Services of BioServe
10.5.2 On Main Customers for BioServe
10.5.3 On the Importance of Biorepositories in Research and Industry
10.5.4 On Technology Use in Biobanks
10.5.5 On Increased Recognition of Biobanking and Harmonisation of Samples
10.5.6 On the Use of Biobanks by the Pharmaceutical Industry
10.5.7 On Commercial Biorepositories/Banks and Scale of Operations
10.5.8 On Commercial and Public Biobanking
10.5.9 On the Most Attractive Segment in Commercial Biobanking
10.5.10 On Biobanking in 2020
10.5.11 On Drivers and Challenges in the Sector
10.6 Dr Frans A.L. van der Horst, Chairman, Dutch Collaborative Biobank
10.6.1 On Importance of Biorepositories in Research and Industry
10.6.2 On Increased Recognition of Biobanking and Harmonisation of Samples
10.6.3 On the Services of Dutch Collaborative Biobank
10.6.4 On Commercial Drivers for Bio-Repositories/Biobanking Market
10.6.5 On Commercial and Public Biobanking
10.6.6 On Sustaining/Recovering Costs
10.6.7 On the Most Attractive Segment in Commercial Biobanking
10.6.8 On Ethical, Legal and Social Issues in Biorepositories/Biobanks
11. Conclusions
11.1 Biobanking for Research and Therapeutics
11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine
11.3 Commercial Drivers of the Biobanking Market
11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth
List of Tables
Table 2.1 Prominent Population-Based Biobanks, 2011
Table 2.2 Prominent Disease-Oriented Biobanks, 2011
Table 2.3 Some Guidelines and Recommendations for Biobanks, 2011
Table 2.4 Laws and Regulations for Biobank-Based Research, Consent Requirements, and Privacy/ Data Protection, 2011
Table 3.1 Some Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2011
Table 4.1 Prominent Companies in the Automated Liquid Handling Market, 2011
Table 4.2 Prominent Companies in Ultra-Low Temperature Freezer Market, 2011
Table 4.3 Prominent LIMS Vendors, 2011
Table 4.4 Prominent Consumables Suppliers for Biobanking, 2011
Table 4.5 Prominent Biorepository Service Providers, 2011
Table 5.1 Estimated Number of Biobanks in Europe, 2011
Table 5.2 Biobanking Market: Grouped Revenue Forecasts, 2010-2016
Table 5.3 Biobanking Market: Grouped Revenue Forecasts, 2017-2022
Table 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2016
Table 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2017-2022
Table 6.3 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2016
Table 6.4 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2017-2022
Table 6.5 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2010-2016
Table 6.6 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2017-2022
Table 6.7 Some Leading Companies in the World Biobanking Market, 2011
Table 6.8 Asterand: Revenue by Segment, 2009 and 2010
Table 6.9 Asterand: Revenue by Geographical Area, 2010
Table 7.1 Stem Cell Banking Market: Overall Revenue Forecast, 2010-2016
Table 7.2 Stem Cell Banking Market: Overall Revenue Forecast, 2017-2022
Table 7.3 Prominent Stem Cell Banks Serving the Research Community, 2011
Table 7.4 Costs of Various Private Cord Blood Banks Worldwide, 2011
Table 7.5 Private Cord Blood Banking Market: Revenue Forecast, 2010-2016
Table 7.6 Private Cord Blood Banking Market: Revenue Forecast, 2017-2022
Table 7.7 Cord Blood Banking Market: Drivers and Restraints, 2012-2022
Table 7.8 Some Prominent Companies in the Cord Blood Banking Market, 2011
Table 7.9 Cryo-Cell International Revenue, 2009-2010
Table 7.10 China Cord Blood Corp Revenue and Subscribers, 2009-2010
Table 7.11 Cryo-Save Revenue and Operating Profit, 2009-2010
Table 7.12 Cryo-Save Revenue by Region, 2010
Table 9.1 SWOT Analysis of the Biobanking Market: Strengths and Weaknesses, 2012-2022
Table 9.2 SWOT Analysis of the Biobanking Market: Opportunities and Threats, 2012-2022
Table 9.3 Information for a Biobank Donor, 2011
Table 11.1 Human Tissue Biobanking Market by Country, 2010, 2016, 2019 & 2022
List of Figures
Figure 2.1 Main Processes Involved in Biobanking, 2011
Figure 2.2 Classification of Biobanks, 2011
Figure 3.1 Biobanking and Pharmaceutical Development, 2011
Figure 4.1 Biobanking, Applications and Users, 2011
Figure 4.2 Functions of LIMS, 2011
Figure 5.1 Overall Biobanking Market: Revenue Forecast, 2010-2016
Figure 5.2 Overall Biobanking Market: Revenue Forecast, 2017-2022
Figure 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2016
Figure 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2017-2022
Figure 6.3 Human Tissue Banking Market: Forecast by Type of Biobank, 2010-2016
Figure 6.4 Human Tissue Banking Market: Forecast by Type of Biobank, 2017-2022
Figure 6.5 Human Tissue Banking Market: Share by Type of Biobank, 2010
Figure 6.6 Human Tissue Banking Market: Share by Type of Biobank, 2022
Figure 6.7 World and US Human Tissue Banking Markets: Revenue Forecasts, 2010-2022
Figure 6.8 Japan, EU 5 and Other Leading Human Tissue Banking Markets: National Revenue Forecasts, 2010-2022
Figure 6.9 Human Tissue Banking: National Market Shares, 2010
Figure 6.10 Human Tissue Banking: National Market Shares, 2016
Figure 6.11 Human Tissue Banking: National Market Shares, 2019
Figure 6.12 Human Tissue Banking: National Market Shares, 2022
Figure 6.13 Commercial Sourcing of Biological Samples, 2011
Figure 6.14 Commercial Banking of Biological Samples, 2011
Figure 6.15 Asterand: Revenues, 2009 & 2010
Figure 6.16 Asterand: Revenue Shares by Region of Destination, 2010
Figure 6.17 Asterand: Revenue Shares by Region of Origin, 2010
Figure 7.1 Stem Cell Banking Market: Revenue Forecast, 2010-2016
Figure 7.2 Stem Cell Banking Market: Revenue Forecast, 2017-2022
Figure 7.3 Twenty-Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
Figure 7.4 Cord Blood Banking Market: Revenue Forecast, 2010-2016
Figure 7.5 Cord Blood Banking Market: Revenue Forecast, 2017-2022
Figure 7.6 Cryo-Cell International Revenue, 2009-2010
Figure 7.7 China Cord Blood Corp Revenue and Subscribers, 2009-2010
Figure 7.8 Cryo-Save Revenue and Operating Profit, 2009-2010
Figure 7.9 Cryo-Save Revenue Shares by Region, 2010
Figure 11.1 Biobanking Market: World Sales Forecast, 2010, 2012, 2016, 2019 & 2022
Companies Listed
Abcellute
Abgene
Adnexus Therapeutics
AFNOR Groupe
AKH Biobank
AlloSource
American National Bioethics Advisory Commission
American Type Culture Collection
Amgen
Analytical Biological Services
ARCH Venture Partners
Asterand
AstraZeneca
Australasian Biospecimen Network (ABN)
Autoscribe
AXM Pharma
Bayer-Schering
Beckman Coulter
Beike Biotechnology
Biobank Ireland Trust
Biobank Japan
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
BioFortis
Biogen Idec
Biogenea-CellGenea
BioLife Solutions
Biomatrica
Biopta
BioRep
BioSeek
BioServe
BioStorage LLC
BioStorage Technologies
BrainNet Europe
Caliper LifeSciences
Canadian Partnership for Tomorrow
CARTaGENE
Cellgene Corporation
Cells4Health
Chemagen
China Cord Blood Corp
Chinese Ministry of Health
CLB/Amsterdam Medical Center
CorCell
Cord Blood America
Cord Blood Registry
CORD:USE (US Public Cord Blood Bank)
CordLife
Cordon Vital (CBR)
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Cryo Bio System
Cryo-Cell International
Cryometrix
Cryo-Save
Cureline
Cybrdi
Danubian Biobank Foundation
deCODE Genetics
Department of Health (DoH, UK)
Draper Laboratory
Duke University Medical Center
Dutch Collaborative Biobank
EGeen
Eli Lilly
Eolas Biosciences
Estonian Genome Project
EuroBioBank
European Commission (EC)
European Health Risk Monitoring (EHRM)
European Medicines Agency (EMA/EMEA)
European Union Group on Ethics (EGE)
Fisher BioServices
Fondazione I.R.C.C.S. Istituto Neurologico C. Besta
Food and Drug Administration (US FDA)
Foundation for the National Institutes of Health
Fundación Istituto Valenciano de Oncología
Fundeni Clinical Institute
Genentech
Generation Scotland
GeneSaver
GeneSys
Genetic Association Information Network (GAIN)
Genizon Biosciences
Genome Quebec Biobank
GenomEUtwin
Genomic Studies of Latvian Population
GenVault
German Dementia Competence Network
GlaxoSmithKline (GSK)
H. Lee Moffitt Cancer Center and Research Institute
Hamilton
Hopital Necker Paris - Necker DNA Bank
Human Tissue Authority (HTA)
Hungarian Biobank
HUNT, Norway
ILSBio LLC
Inbiobank
Inbiomed
Indivumed
INMEGEN
Institut National de la Santé et de la Recherche Médicale (INSERM)
Integrated BioBank of Luxembourg
International Agency for Research on Cancer (IARC)
International Air Transport Association (IATA)
International Organization for Standardization (ISO)
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
Kaiser Permanente
KORA-gen
LabVantage Solutions
LabWare
Leiden University Medical Center
LifebankUSA
LifeGene
LifeStem
Malaysian Cohort Project
Matrical Biosciences
Matrix
Medical Research Council (MRC)
Medical University of Gdansk
Merck & Co.
Merck Sharp & Dohme Limited (MSD)
Merck-Serono
Micronic
Millennium (Takeda Oncology Company)
MVE-Chart
National Cancer Institute (NCI)
National DNA Bank (US)
National Human Genome Research Institute (NHGRI)
National Institute of Environmental Health
National Institutes of Health (NIH)
National Public Health Institute
National Research Ethics Service (NRES)
NeoCodex
NeoStem
Neuromuscular Bank of Tissues and DNA Samples
New Brunswick Scientific
NEXUS Biosystems
Northwest Regional Development Agency
Novacare Bio-Logistics
Novartis
NUgene Project
Ocimum Biosolutions
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
Oxagen
Pacific Bio-Material Management
PathServe
Perkin Elmer
Pfizer
Pharmagene Laboratories Trustees Limited
Polaris Ventures
Pop-Gen (University Hospital Schleswig-Holstein)
PrecisionMed
Prevention Genetics
ProMedDx
Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE)
ProteoGenex
Public Population Projects in Genomics (P3G Consortium)
Qiagen
RAND Corporation
Regenetech
REMP
Reproductive Genetics Institute (RGI)
Research Centre of Vascular Diseases, University of Milan
Rhode Island BioBank, Brown University
Roche
RTS Life Science
Saga Investments LLC
SampleNavigator Laboratory Automation Systems
Sanofi
SANYO Biomedical
Scottish Government
Seattle Genetics
Sejtbank (Hungarian Cord Blood Bank)
SeqWright DNA Technology Services
SeraCare Life Sciences
Singapore Tissue Network
StarLIMS
Steelgate
Stem Cell Authority
Stem Cells for Safer Medicine (SC4SM)
Stem Cells Research Forum of India
Stemride International
Taiwan Biobank
Taizhou Biobank
TAP
Tecan
The Automation Partnership
The Sorenson Molecular Genealogy Foundation (SMGF)
Thermo Fisher Scientific
Thermogenesis
Tissue Bank Cryo Center (Bulgaria)
Tissue Solutions
Titan Pharmaceuticals
TotipotentSC
Trinity Biobank
Tumorothèque Necker-Entants Malades
UK Biobank
UK Stem Cell Bank
UmanGenomics
Umeå University
University Hospital Angers
University Medical Center Gent
University of Massachusetts Stem Cell Bank
University of Tuebingen, Department of Medical Genetics
US Biomax
Västerbotten County Council
ViaCord
Wellcome Trust
Wellcome Trust Case-Control Consortium (WTCCC)
Western Australian Genome Health Project
Wheaton Science International
Wisconsin International Stem Cell (WISC) Bank
World Health Organization (WHO)
Zhejiang Lukou Biotechnology Co
